Allen Jeremias, MD, MSc; Ajay Kirtane, MD, SM
Potential Financial Conflicts of Interest:Consultancies: A. Kirtane (Medtronic Vascular). Honoraria: A. Kirtane (Boston Scientific).
Requests for Single Reprints: Allen Jeremias, MD, MSc, Division of Cardiovascular Medicine, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794; e-mail, email@example.com.
Current Author Addresses: Dr. Jeremias: Division of Cardiovascular Medicine, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794.
Dr. Kirtane: Division of Cardiovascular Medicine, New York-Presbyterian Hospital, 161 Fort Washington Avenue, New York, NY 10032.
Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization compared with bare-metal stents. However, the safety of drug-eluting stents has been called into question because of an apparent increase in late stent thrombosis, a frequently fatal event. A substantial body of research has focused on determining the magnitude of these competing events, often reaching contradictory results even with analyses of the same data. Although larger, adequately powered, randomized trials are needed to fully assess the net clinical effects of drug-eluting stents compared with bare-metal stents, the evidence seems to suggest that the net clinical benefit of drug-eluting stents may outweigh their risks. The evidence is clearer that premature discontinuation of antiplatelet therapy is an important trigger for stent thrombosis; therefore, patients who are candidates for implantation of drug-eluting stents should be screened for their ability to receive and tolerate uninterrupted antiplatelet therapy longer than is necessary with bare-metal stents. The evidence suggests that drug-eluting stents relieve obstructive coronary artery disease, provide durable mechanical results, and do more good than harm, but all patients also should be given antiplatelet and other optimal medical therapies to achieve the best outcomes.
Table 1. Clinical Events in Pivotal Trials of Sirolimus- and Paclitaxel-Eluting Stents*
Appendix Table 1. Definition of Stent Thrombosis according to the Academic Research Consortium*
Appendix Table 2. Certainty of Stent Thrombosis Events
Table 2. Pooled Data from Pivotal Trials of Sirolimus- and Paclitaxel-Eluting Stents*
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Jeremias A, Kirtane A. Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. Ann Intern Med. 2008;148:234–238. doi: 10.7326/0003-4819-148-3-200802050-00199
Download citation file:
Published: Ann Intern Med. 2008;148(3):234-238.
Cardiology, Coronary Heart Disease, Percutaneous Coronary Intervention.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use